This page contains a Flash digital edition of a book.
Supporting Innovation


Discovery Research Grants (Grants-in-Aid) support high-quality research projects that will enhance our understanding of Crohn’s and colitis and have the potential to cure or more effectively control the diseases. These grants build on the achievements and strengths of the world-class IBD research community in Canada by supporting the pipeline for discovery of new therapies. The research projects funded by our organization are devoted to finding the causes of Crohn’s and colitis (environmental triggers and genetic markers) and developing new treatments (blocking inflammation, treating complications, improving therapy, and creating healthy gut ecosystems).


Finding The Causes And Triggers ENVIRONMENTAL TRIGGERS


Discovering how what we eat, how we live and what bacteria we have in our guts impacts on Crohn’s and colitis.


Researcher Institution


Dr. Andre Buret University of Calgary


Project


Acute infection with Camplylobacter jejuni initiates and/or exacerbates intestinal inflammation in IBD


patients. Dr. Buret is studying how Campylobacter jejuni may disrupt the gut microbiome and trigger the IBD disease process in motion. This work may shed new light on the mechanisms responsible for intestinal inflammation in IBD, and will help identify novel therapeutic targets in IBD.


Keywords: microflora biofilms; IBD pathophysiology; immune misreading mechanism; bacterial infections; Camplylobacter jejuni.


Dr. Scott Gray-Owen


University of Toronto


In the search to understand a potential link between microbes and Crohn’s disease, Dr. Gray-Owen is


investigating a bacterial pathogen called “adherent and invasive E. coli” (AIEC). AIEC appears to stick to and penetrate lining of the gut and potentially contribute to the chronic inflammation seen in IBD. These studies will provide new insights into the cause of IBD and may lead to novel strategies to either prevent Crohn’s disease or interrupt the inflammatory process.


Keywords: adherent and invasive E. coli; Crohn’


s disease; NOD2; bacterial infections. $119,445 (Year 3 of 3) Investment $118,705 (Year 3 of 3)


RESEARCH REPORT 2013 | 14


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32